I've been fascinated with the brouhaha that's been going on with Chinese small-cap stocks. Of course, when I say "fascinated," I mean fascinated like when everyone on the highway slows down to stare at a multi-car wreck.
Unless you've got money invested, it's tough to figure out who to root for in the whole mess. On one side, you've got these apparently fast-growing Chinese companies that came into the public markets through reverse mergers -- which is sort of like visiting a friend's house by sneaking in through an open window. Most of these companies appear to be showing gangbuster growth, but at the very least their management teams have had a heck of a time clearly communicating with investors.
On the other side of the tussle, we've got self-styled crusaders out to crush the supposedly fraudulent companies. Many (most?) among this guerilla band short the stocks that they attack, hoping to profit as the stocks' prices fall. While there has been some really good work done by some of the sleuths, as more and more blood enters the water it seems that anyone who can come up with a noble-looking logo is ready to take potshots at Chinese small caps that they're shorting.
Like I said, it's tough to wave a flag for either side.
Getting down with diligence
I was struck again by how nutty it's gotten after covering three separate Chinese stocks yesterday that were reeling after bearish reports. Yongye International
Of the three, it was China-Biotics' tumble that stood out the most to me. It appeared that the stock's decline was driven by a blog post on Seeking Alpha from an amateur investor named Gisli Eyland, who posts under the name "Sportgamma" and sums his approach as "Sports business meets value investing."
There was really nothing wrong with Eyland's post on China-Biotics. He notes that he's had some concerns about the company and then details some simple diligence he tried to do to allay those concerns. Eyland apparently scoured publicly available documents for China-Biotics and then sent out a series of emails to the company and third parties to try and verify or question what he'd read. All but one of his emails -- which included attempting to contact large companies like Wal-Mart and Unilever -- went unanswered.
As a result, Eyland was left with the same questions he started with and a queasy feeling in his gut. He said, "I'm inconclusive whether China Biotics is indeed a fraud or a rose bud among cabbages, but what I do know is that I have a huge information disadvantage." So he shared his decision to sell his China-Biotics shares.
Somebody's getting greedy
Interestingly, in the midst of the sell-off there didn't seem to be much notice that investor Richard Azar continues building a large stake in the company. Yesterday, the company filed a "Form 4" showing that Azar increased his stake by 178,500 shares on May 17. That follows a filing the day prior reporting a holding increase of nearly 400,000 shares. Based on his holding as of Tuesday, Azar's stake at yesterday's price is worth nearly $32 million.
Now who exactly is Richard Azar? Good question and one that I didn't initially have an answer for. Interestingly, there is little information readily available about him. Based on a Facebook profile, he's a snappy dresser and a fan of Boccelli, Shakespeare, and Charlie Rose. More importantly, it appears that he is a big-time Trinidadian investor who is a big fan of Warren Buffett. His name is even mentioned a couple of times in Roger Lowenstein's Buffett: The Making of an American Capitalist.
Myopia?
Even smart investors do stupid things, and perhaps Azar is throwing good money at a bad company. However, it boggles my mind that investors in the China small-cap space are so scared out of their minds that they'd allow a stock to be knocked down more than 10% based on the musings of an amateur investor while a big fish is throwing real money at the shares.
Not that I'm all that surprised by this -- to some extent it echoes the crazy sell-off in China Shen Zhou Mining
If ever there were an environment of "shoot many times in the face first and maybe, possibly ask questions later," it exists right now with Chinese small caps.
Boy, the sidelines are comfortable
I started out by saying that I'm fascinated by what's unfolding here, and I'd bet my left arm that I'll continue to be wowed by new developments. While I've considered the possibility of entering the fracas by investing in a basket of these shunned stocks -- and thereby hoping that some big gainers would offset any proven-out frauds -- I'm still currently enjoying the view from the sidelines, particularly since I've been finding good opportunities in stocks that are much easier to get my arms around.
Now I know you have something to say about the Chinese small-cap showdown, so head down to the comments section and sound off!
